# Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

> **NCT07158346** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 49 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** L03RD1
- **DRUG:** L03RD2
- **DRUG:** CT-L03

## Key facts

- **NCT ID:** NCT07158346
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-18
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-23
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158346, "Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07158346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*